| P2093 | author name string | Carlos Cepeda | |
| | Elizabeth A Wang | |
| | Michael S Levine | |
| | Jane Y Chen | |
| P2860 | cites work | Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter | Q24310836 |
| | Synaptic organisation of the basal ganglia | Q24544917 |
| | Neural substrates of cognitive inflexibility after chronic cocaine exposure | Q24648658 |
| | Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease | Q24657764 |
| | Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's | Q24797858 |
| | Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease | Q27015687 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway | Q48872243 |
| | The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method. | Q51120870 |
| | Post-receptor mechanisms underlying striatal long-term depression. | Q51627778 |
| | The contribution of the medial prefrontal cortex, orbitofrontal cortex, and dorsomedial striatum to behavioral flexibility. | Q51978106 |
| | Regional and postnatal heterogeneity of activity-dependent long-term changes in synaptic efficacy in the dorsal striatum. | Q52165392 |
| | Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. | Q52222727 |
| | Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations | Q68432439 |
| | The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat | Q69051666 |
| | Compartmental origins of striatal efferent projections in the cat | Q69115669 |
| | Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes | Q69357304 |
| | Iontophoresis in the neostriatum of awake, unrestrained rats: Differential effects of dopamine, glutamate and ascorbate on motor- and nonmotor-related neurons | Q72059851 |
| | Dopamine selects glutamatergic inputs to neostriatal neurons | Q73042964 |
| | Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons | Q28259633 |
| | Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease | Q28262372 |
| | The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease | Q28264134 |
| | Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus | Q28299834 |
| | Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease | Q28302222 |
| | Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission | Q28343012 |
| | Profound neuronal plasticity in response to inactivation of the dopamine transporter | Q28508907 |
| | Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32 | Q28570233 |
| | Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor | Q28577705 |
| | Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice | Q28590689 |
| | Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 |
| | D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons | Q29615480 |
| | The functional anatomy of basal ganglia disorders | Q29617461 |
| | Huntington's Disease | Q30306484 |
| | Synapsins differentially control dopamine and serotonin release | Q30433690 |
| | Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease | Q30490632 |
| | Thalamic gating of corticostriatal signaling by cholinergic interneurons. | Q30583147 |
| | Stimulant-induced adaptations in neostriatal matrix and striosome systems: transiting from instrumental responding to habitual behavior in drug addiction. | Q31148567 |
| | Short-term effects of olanzapine in Huntington disease. | Q32107515 |
| | Pharmacological management of Huntington's disease: an evidence-based review | Q33250216 |
| | Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease | Q33573371 |
| | Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity | Q33656355 |
| | Replicating Huntington's disease phenotype in experimental animals | Q33749061 |
| | Tetrabenazine is neuroprotective in Huntington's disease mice | Q33863426 |
| | Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice | Q33869789 |
| | Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease | Q33878001 |
| | Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation | Q33922831 |
| | Neuronal cell death in Huntington's disease: a potential role for dopamine | Q33934225 |
| | Different corticostriatal integration in spiny projection neurons from direct and indirect pathways | Q33944484 |
| | The basal ganglia | Q33970931 |
| | Huntington's disease: the challenge for cell biologists | Q34106564 |
| | Cholinergic interneuron characteristics and nicotinic properties in the striatum | Q34159449 |
| | Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial | Q34231219 |
| | Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals | Q34305700 |
| | Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging | Q34335008 |
| | Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue | Q41530863 |
| | The cortico-nigral fibre tract. An experimental Fink-Heimer study in cats. | Q41812196 |
| | Genetic dissection of behavioral flexibility: reversal learning in mice | Q41881959 |
| | Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation | Q42457188 |
| | Early onset Huntington disease: a neuronal degeneration syndrome | Q42466838 |
| | Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the cortico-nigral circuits | Q42472580 |
| | Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons | Q42482886 |
| | A measure of striatal function predicts motor stereotypy. | Q42485259 |
| | Early loss of neostriatal striosome neurons in Huntington's disease | Q42487671 |
| | Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. | Q42496467 |
| | Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro | Q42498386 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death | Q42513244 |
| | Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice | Q42513638 |
| | Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia | Q42517856 |
| | Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. | Q42523227 |
| | Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats | Q42523823 |
| | Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease | Q42525075 |
| | Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice | Q42528338 |
| | Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation | Q42688388 |
| | Hyperdopaminergic status in experimental Huntington disease | Q42933401 |
| | Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia | Q43073344 |
| | Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects | Q43271068 |
| | Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat | Q43479489 |
| | Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro | Q43517989 |
| | D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons | Q43582794 |
| | Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers | Q43700723 |
| | Regional differences in the expression of corticostriatal synaptic plasticity | Q43742971 |
| | Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease | Q43925468 |
| | Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease | Q43992558 |
| | Regulation of neurotransmitter release by synapsin III. | Q44012215 |
| | The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease | Q44029787 |
| | Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia | Q44046947 |
| | Striatal neurochemical changes in transgenic models of Huntington's disease | Q44059847 |
| | Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. | Q44187993 |
| | Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease | Q44250429 |
| | Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. | Q44306949 |
| | Transgenic rat model of Huntington's disease | Q44350467 |
| | Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. | Q44400030 |
| | Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons | Q44463501 |
| | Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity | Q44478915 |
| | Ziprasidone in Huntington's disease: the first case reports | Q44761187 |
| | Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease | Q44806645 |
| | Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals | Q44905912 |
| | Repetitive behaviors in monkeys are linked to specific striatal activation patterns. | Q45030470 |
| | By carrot or by stick: cognitive reinforcement learning in parkinsonism | Q45140702 |
| | Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 |
| | Sexual disorders in Huntington's disease | Q45289525 |
| | Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease | Q45292176 |
| | Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease | Q45292268 |
| | Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine | Q45292440 |
| | Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease | Q45292669 |
| | Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene | Q37432151 |
| | Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation | Q37540059 |
| | The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease | Q37646362 |
| | Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections | Q37706532 |
| | Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum | Q37723743 |
| | Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms | Q37731940 |
| | Acetylcholine-dopamine balance hypothesis in the striatum: an update | Q37768850 |
| | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. | Q37930190 |
| | Pharmacologic approaches to the treatment of Huntington's disease | Q37945478 |
| | An evidence-based approach in the treatment of Huntington's disease. | Q37969340 |
| | Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons | Q38323909 |
| | Impairments in the acquisition, retention and selection of spatial navigation strategies after medial caudate-putamen lesions in rats | Q38593346 |
| | A zinc finger protein Zfp521 directs neural differentiation and beyond | Q39448048 |
| | Treatment of Huntington's chorea with bromocriptine | Q39820310 |
| | Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. | Q39933436 |
| | Chemical pathology of Huntington's disease | Q40217253 |
| | The psychology of perserverative and stereotyped behaviour | Q40576856 |
| | Oxidative stress, glutamate, and neurodegenerative disorders | Q40618533 |
| | Regionally selective roles of the rat's striatum in modality-specific discrimination learning and forelimb reaching | Q41230091 |
| | Modulation of dopamine neuronal activity by glutamate receptor subtypes | Q41509305 |
| | Executive and mnemonic functions in early Huntington's disease | Q45293389 |
| | Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation | Q45293460 |
| | Heterogeneous dopamine receptor changes in early and late Huntington's disease | Q45293500 |
| | PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease | Q45294163 |
| | Orexin loss in Huntington's disease. | Q45295272 |
| | Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum | Q45295278 |
| | Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes | Q45295568 |
| | Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. | Q45298559 |
| | Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia | Q45299102 |
| | Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons | Q45299250 |
| | Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease | Q45299623 |
| | Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 |
| | Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease | Q45300523 |
| | Predictive test for Huntington's chorea | Q45300600 |
| | Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. | Q45302139 |
| | Risky decision making in Huntington's disease | Q45302543 |
| | Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations | Q45302799 |
| | Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin | Q45302968 |
| | Hypersexual features in Huntington's disease. | Q45303521 |
| | Effects of DA agonist in Huntington disease hyperkinesia | Q45304087 |
| | Acute treatment of Huntington's chorea with lisuride | Q45304681 |
| | Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease | Q45305026 |
| | SPECT study of the nigrostriatal dopaminergic system in Huntington's disease | Q45305746 |
| | Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice | Q45306356 |
| | Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo | Q45306581 |
| | Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. | Q45307012 |
| | Mechanisms for synapse specificity during striatal long-term depression. | Q45937925 |
| | Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices | Q46133563 |
| | Pivotal role of early B-cell factor 1 in development of striatonigral medium spiny neurons in the matrix compartment | Q46161329 |
| | Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. | Q46279749 |
| | Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum | Q46717751 |
| | Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. | Q47831483 |
| | Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys | Q48088886 |
| | The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine | Q48173382 |
| | Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. | Q48226289 |
| | Effects of medial and lateral caudate-putamen lesions on place- and cue-guided behaviors in the water maze: relation to thigmotaxis | Q48231377 |
| | Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo | Q48249875 |
| | Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory | Q48285410 |
| | Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones | Q48301290 |
| | Stimulation of the subthalamic nucleus enhances the release of dopamine in the rat substantia nigra | Q48331606 |
| | The human striatum is necessary for responding to changes in stimulus relevance | Q48357068 |
| | Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor | Q48461797 |
| | Huntington disease | Q48465200 |
| | The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat | Q48601307 |
| | The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems | Q48614166 |
| | Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. | Q48616333 |
| | Dissociable roles of the ventral, medial and lateral striatum on the acquisition and performance of a complex visual stimulus-response habit | Q48622491 |
| | D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance. | Q48723732 |
| | Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol | Q34411138 |
| | Under the curve: critical issues for elucidating D1 receptor function in working memory | Q34470592 |
| | Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. | Q34521936 |
| | The thalamostriatal system: a highly specific network of the basal ganglia circuitry | Q34550491 |
| | Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry | Q34707716 |
| | Differential electrophysiological changes in striatal output neurons in Huntington's disease. | Q34764514 |
| | Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia | Q35044635 |
| | Altered Balance of Activity in the Striatal Direct and Indirect Pathways in Mouse Models of Huntington's Disease | Q35055022 |
| | In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease | Q35116551 |
| | Neuropsychiatry of Huntington's disease | Q35236937 |
| | The neostriatal mosaic: multiple levels of compartmental organization | Q35318347 |
| | Differential effects of M1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning | Q35506425 |
| | Dichotomous anatomical properties of adult striatal medium spiny neurons | Q35607269 |
| | Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice | Q35804816 |
| | Dopaminergic signaling and striatal neurodegeneration in Huntington's disease | Q35839434 |
| | Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement | Q35844174 |
| | Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect | Q35913010 |
| | Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice | Q35982759 |
| | Levodopa responsive parkinsonism in an adult with Huntington's disease | Q36318912 |
| | Knock-in mouse models of Huntington's disease | Q36358874 |
| | Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? | Q36380359 |
| | Biological sources of inflexibility in brain and behavior with aging and neurodegenerative diseases | Q36434965 |
| | Striatal dopamine influences the default mode network to affect shifting between object features | Q36435515 |
| | Excitotoxic injury of the neostriatum: a model for Huntington's disease | Q36586040 |
| | Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated | Q36599964 |
| | Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. | Q36602125 |
| | Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse | Q36713909 |
| | A systematic review of the treatment studies in Huntington's disease since 1990. | Q36719669 |
| | Obsessive and compulsive symptoms in prediagnosed Huntington's disease | Q36856810 |
| | Motor function and dopamine release measurements in transgenic Huntington's disease model rats | Q36916504 |
| | Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition | Q36989252 |
| | Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice | Q37072467 |
| | Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. | Q37093708 |
| | Genes, cognition and brain through a COMT lens | Q37384503 |
| P921 | main subject | dopamine | Q170304 |
| | Huntington's disease | Q190564 |
| P304 | page(s) | 114 | |
| P577 | publication date | 2013-07-04 | |
| P1433 | published in | Frontiers in Neuroscience | Q2177807 |
| P1476 | title | Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility | |
| P478 | volume | 7 | |